Glen Eagle Advisors’s Unity Biotechnology UBX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $746 | Buy |
1,942
+838
| +76% | +$322 | ﹤0.01% | 956 |
|
|
2025
Q1 | $1.15K | Hold |
1,104
| – | – | ﹤0.01% | 916 |
|
|
2024
Q4 | $1.08K | Hold |
1,104
| – | – | ﹤0.01% | 954 |
|
|
2024
Q3 | $1.62K | Hold |
1,104
| – | – | ﹤0.01% | 936 |
|
|
2024
Q2 | $1.49K | Hold |
1,104
| – | – | ﹤0.01% | 943 |
|
|
2024
Q1 | $1.81K | Hold |
1,104
| – | – | ﹤0.01% | 919 |
|
|
2023
Q4 | $2.13K | Hold |
1,104
| – | – | ﹤0.01% | 857 |
|
|
2023
Q3 | $2.65K | Sell |
1,104
-1
| -0.1% | -$2 | ﹤0.01% | 817 |
|
|
2023
Q2 | $2.82K | Buy |
1,105
+681
| +161% | +$1.74K | ﹤0.01% | 822 |
|
|
2023
Q1 | $691 | Hold |
424
| – | – | ﹤0.01% | 980 |
|
|
2022
Q4 | $1.16K | Sell |
424
-1
| -0.2% | -$3 | ﹤0.01% | 995 |
|
|
2022
Q3 | $1.68K | Hold |
425
| – | – | ﹤0.01% | 890 |
|
|
2022
Q2 | $2.4K | Buy |
425
+134
| +46% | +$755 | ﹤0.01% | 810 |
|
|
2022
Q1 | $3.26K | Buy |
291
+237
| +439% | +$2.65K | ﹤0.01% | 758 |
|
|
2021
Q4 | $785 | Hold |
54
| – | – | ﹤0.01% | 872 |
|
|
2021
Q3 | $1.61K | Buy |
54
+23
| +74% | +$686 | ﹤0.01% | 951 |
|
|
2021
Q2 | $1.44K | Hold |
31
| – | – | ﹤0.01% | 956 |
|
|
2021
Q1 | $1.86K | Buy |
+31
| New | +$1.86K | ﹤0.01% | 885 |
|